8-K: Coherus BioSciences Reports Full Year 2023 Results, Restructures to Focus on Oncology

Coherus BioSciences divested its ophthalmology franchise, reduced its workforce by 30%, and reported full year 2023 financial results, highlighting a strategic shift towards oncology.

Summary

• Coherus BioSciences reported a net revenue of $91.5 million for the fourth quarter of 2023 and $257.2 million for the full year.
• UDENYCA net sales were $36.2 million in Q4 and $127.1 million for the year, while CIMERLI net sales reached $52.4 million in Q4 and $125.4 million for the year.
• The company successfully launched LOQTORZI and UDENYCA ONBODY in Q1 2024.
• A corporate restructuring included a 30% workforce reduction, expected to save over $25 million annually.
• Coherus divested its ophthalmology franchise to Sandoz for $170 million upfront plus $17.8 million for inventory and prepaid assets.
• The company plans to prepay $175 million of its term loan, reducing annual interest payments by approximately 70%.
• 2024 R&D and SG&A expenses are projected to be between $250 and $265 million, a decrease from $301.5 million in 2023.
• The milestone payment to Junshi Biosciences for toripalimab NPC approval has been restructured, with $12.5 million due in Q2 2024 and the remainder in Q1 2025.
• UDENYCA market share was 26% as of March 1, 2024.
• LOQTORZI has been launched and is recommended by NCCN guidelines as a preferred treatment for NPC.
• Coherus is advancing its immuno-oncology pipeline, including a clinical collaboration with INOVIO and new data for casdozokitug.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments such as the divestiture, cost reductions, and new product launches, the significant net losses, workforce reduction, and delayed milestone payment temper the overall sentiment. The strategic shift towards oncology is promising, but the financial challenges are concerning.

Positives

• The divestiture of the ophthalmology franchise provides a significant cash infusion of $170 million.
• The reduction in workforce is expected to result in substantial cost savings of over $25 million annually.
• The prepayment of the term loan will significantly reduce interest expenses by approximately 70%.
• UDENYCA sales are growing, with a 10% increase in Q4 2023 compared to Q3 2023.
• The successful launch of UDENYCA ONBODY and LOQTORZI indicates strong market acceptance.
• The company is making progress in its immuno-oncology pipeline with promising clinical data and planned IND filings.
• The company has reduced its net loss for the full year 2023 compared to 2022, from $291.8 million to $237.9 million.

Negatives

• The company experienced a net loss of $79.7 million in the fourth quarter of 2023.
• Cost of goods sold increased significantly in 2023, including a $47 million charge for the write-down of slow-moving YUSIMRY inventory.
• Cash, cash equivalents, and investments decreased from $191.7 million at the end of 2022 to $117.7 million at the end of 2023.
• The company is undergoing a significant workforce reduction of 30%, which may impact morale and operations.
• The restructuring of the toripalimab milestone payment delays $12.5 million of the payment until Q1 2025.

Risks

• The company faces risks inherent in the clinical drug development process.
• There are risks related to the company's existing and potential collaboration partners.
• The company faces risks related to its competitive position in the market.
• The company faces risks related to the regulatory approval process, including the speed of regulatory review and the timing of regulatory filings.
• There is a risk of FDA review issues.
• The company faces the risk of competition.
• There is a risk that the company is unable to complete commercial transactions.
• The company faces the risks and uncertainties of possible litigation.

Future Outlook

Coherus is focused on driving revenues, reducing costs, and advancing its oncology pipeline, with a goal of long-term shareholder value. The company expects to realize value from its pipeline and is better positioned to execute its mission of extending the lives of cancer patients.

Management Comments

• Throughout 2023, Coherus demonstrated significant progress in transforming the Company's business model and product portfolio for long-term sustainable growth, said Denny Lanfear, Coherus Chairman and Chief Executive Officer.
• We are clearly focused on driving our revenues, reducing our costs, and advancing our pipeline, with constant attention to long-term shareholder value.
• The divestiture of CIMERLI and debt paydown improves our capital structure and sharpens our focus on oncology.
• With a robust portfolio of FDA-approved products and a promising immuno-oncology pipeline, we are now better positioned than ever to execute on our mission of extending the lives of cancer patients.

Industry Context

This announcement reflects a broader trend in the biopharmaceutical industry where companies are streamlining operations and focusing on core therapeutic areas. The divestiture of the ophthalmology franchise and the focus on oncology aligns with the industry's move towards specialization and targeted therapies. The launch of new products and the advancement of the immuno-oncology pipeline are also consistent with the industry's emphasis on innovation and new treatment modalities.

Comparison to Industry Standards

• Coherus's revenue growth of $257.2 million for 2023 is a positive sign, but it is important to compare this to other biosimilar companies like Amgen and Sandoz, who have much larger revenue bases.
• The 30% workforce reduction is a significant move, and it is similar to actions taken by other biotech companies facing financial pressures, such as Biogen and Alnylam, who have also implemented cost-cutting measures.
• The divestiture of the ophthalmology franchise is a strategic move to focus on oncology, which is a common strategy among companies seeking to optimize their portfolios, similar to how Pfizer divested its consumer healthcare business to focus on pharmaceuticals.
• The launch of UDENYCA ONBODY and LOQTORZI is a positive step, but their market uptake needs to be compared to similar product launches by competitors like Teva and Mylan.
• The company's R&D spending of $109.4 million for 2023 is relatively low compared to larger pharmaceutical companies, which typically invest billions in R&D, such as Roche and Novartis.

Stakeholder Impact

• Shareholders may be concerned about the net losses and the decrease in cash reserves, but may be encouraged by the strategic shift towards oncology and the potential for future growth.
• Employees will be significantly impacted by the 30% workforce reduction, leading to job losses and potential morale issues.
• Customers will benefit from the launch of new products like UDENYCA ONBODY and LOQTORZI, providing new treatment options.
• Suppliers may be affected by the company's restructuring and cost-cutting measures.
• Creditors will be impacted by the prepayment of the term loan and the reduction in interest payments.

Next Steps

• Coherus plans to prepay $175 million of its term loan on or before April 1, 2024.
• The company plans to file an Investigational New Drug (IND) application in the second quarter of 2024 for CHS-1000.
• Coherus will continue to advance its immuno-oncology pipeline, including clinical trials for casdozokitug and CHS-114.
• The company will present new preclinical data for CHS-1000 at the 2024 AACR Annual Meeting in April.

Key Dates

Keywords

Oncology, Immunotherapy, Biosimilars, UDENYCA, CIMERLI, LOQTORZI, Restructuring, Cost Reduction, Clinical Trials, Pharmaceuticals